Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
ADMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.21 - $25.67
Previous CloseN/A
Volume407.39K
Average Volume (3M)2.93M
Market Cap
$4.34B
Enterprise Value$835.68M
Total Cash (Recent Filing)$71.63M
Total Debt (Recent Filing)$82.01M
Price to Earnings (P/E)21.5
Beta1.05
Next Earnings
Aug 06, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding238,734,250
10 Day Avg. Volume4,324,333
30 Day Avg. Volume2,934,820
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-10.46
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda1.77
Forecast
1Y Price Target
$30.67Price Target Upside68.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ADMA Biologics News
PremiumCompany Announcements
ADMA Biologics Holds Annual Stockholders Meeting
PremiumCompany Announcements
ADMA Biologics Reports Strong Growth and Strategic Advances
PremiumCompany Announcements
ADMA Biologics Reports Strong Q1 2025 Financial Growth
PremiumCompany Announcements
ADMA Biologics Announces $500M Share Repurchase Program
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe filing of ADMA's 10-K is seen as a clearing event, resolving previous accounting concerns and shifting focus to the expansion of ASCENIV.
Supply ChainThe recent long-term plasma contracts have alleviated supply concerns, supporting the growth potential for ASCENIV.
Bears Say
Guidance And ExpectationsKey triggers behind the sell-off were a more modest than expected 2025 guide, ambiguity on bullish implications of the enhanced supply agreements, and valuation friction.
Ownership Overview
3.25% Insiders
21.69% Mutual Funds
14.79% Other Institutional Investors
33.62% Public Companies and Individual Investors
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
ADMA Biologics lowest stock price was $10.21 and its highest was $25.67 in the past 12 months.
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $4.34B.
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is Aug 06, 2025 which is in 37 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on May 07, 2025. The company reported $0.136 earnings per share for the quarter, missing the consensus estimate of $0.153 by -$0.017.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is 0.14.
How many shares outstanding does ADMA Biologics have?
ADMA Biologics has 238,734,250 shares outstanding.
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of $0.136 in its last earnings report, missing expectations of $0.153. Following the earnings report the stock price went down -10.208%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
ADMA Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.67 (68.89% Upside)
$30.67 (68.89% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $9.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.84%
12-Months-Change
Fundamentals
Return on Equity
78.45%
Trailing 12-Months
Asset Growth
45.51%
Trailing 12-Months
Company Description
ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for ADMA Biologics reflected strong financial growth and operational achievements, notably with the FDA approval for a new production process and raised financial guidance. However, challenges such as voluntary product withdrawals and high operating expenses were also evident. Overall, the sentiment remains optimistic, supported by strategic initiatives and financial strength.Read More>ADMA Stock 12 Month Forecast
Average Price Target
$30.67
▲(68.89%Upside)